Search

Over the past two decades, nanotechnology has captured significant interest, especially in the medical field, where the unique characteristics of nanoscale particles offer substantial advantages. The family of nanosized materials, specifically iron oxide nanoparticles (IONPs), has emerged as promising due to their magnetic properties, biocompatibility, and substantial surface area for therapeutic molecule attachment. The review explores various strategies to enhance the antibacterial properties of IONPs, such as metal doping, which modifies their physicochemical, biological, electrical, and optical properties. Metal-doped IONPs, including those with nickel, copper, zinc, selenium, molybdenum, gold, and others, have shown that they effectively eradicate viruses and bacteria. The mechanisms behind their enhanced antibacterial activity involve generating reactive oxygen species (ROS), inhibiting antibiotic-resistant genes, disrupting cell walls and DNA, dysfunction of efflux pumps, and internalizing nanoparticles. The review also addresses the potential toxicity of IONPs, highlighting factors such as their dimension, form, and outermost layers, which change how they affect the overall condition of cellular structures. Surface coatings using polymers and essential oils are among the strategies being investigated as potential ways to reduce toxicity. This review additionally looks into IONPs' drug delivery potential for antibiotics and antifungals. The integration of IONPs with various pharmaceutical compounds and their controlled release mechanisms are also detailed. The review concludes by offering a positive outlook on the potential enhancements and prospects of IONPs. Challenges in synthesis technologies, size tuning, and surface alteration are acknowledged, emphasizing the need for continued research to fully harness the capabilities of IONPs in biomedical applications., Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Saba et al.)

Cancer cells proliferate using various mechanisms. One mechanism of preventing tumor cell growth is blockade of the cyclin-dependent kinase (CDK) 4/6 axis. Multiple CDK 4/6 inhibitors - ribociclib, palbociclib, and abemaciclib - have significantly improved progression-free survival rates. However, they can cause hepatotoxicity. We present a case of a 67-year-old female who was diagnosed with stage 1C invasive ductal carcinoma. She was treated with letrozole and ribociclib due to recurrence as metastatic disease, but within 10 days, she developed transaminitis. She then started palbociclib but experienced elevated transaminases within two weeks, needing discontinuation of palbociclib. Subsequent positron-emission tomography/computed tomography imaging showed disease progression, and she was started on fulvestrant. We considered adding abemaciclib, but the patient declined and has had stable disease for more than a year on fulvestrant. CDK 4/6 inhibitors are used to treat metastatic breast cancer and are generally well tolerated. The most common side effect is neutropenia; however, our patient developed transaminitis. The novelty of our case is the development of hepatotoxicity even after the introduction of another CDK 4/6 inhibitor, indicating at least some degree of class effect. In summary, CDK 4/6 inhibitors have significantly improved outcomes in hormone-positive metastatic breast cancers. However, a small percentage suffer from hepatic injury enough to warrant discontinuation of the drug, and we must continue to assess the risk versus benefit profile when offering them to our patients., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Wani et al.)

Chronic cough is a common chief complaint in ambulatory clinics. Unlike most cases that are caused by upper airway cough syndrome, gastroesophageal reflux disease, asthma, and non-asthmatic eosinophilic bronchitis, chronic cough can also be the presenting feature of a Chiari malformation. Our case is that of a 39-year-old female who had a chronic cough associated with shortness of breath, and when severe, associated with loss of consciousness. Her cough was refractory to conventional management. Further workup including pulmonary functions tests (PFT), laryngoscopy, high-resolution CT of the chest, an upper GI series, and esophageal pH manometry study were all normal. An MRI of her brain was obtained due to her syncopal episodes and revealed findings concerning a type 1 Chiari malformation. She subsequently underwent a Chiari decompression with patchy duraplasty and tonsilloplasty with cervical vertebrae 1 and 2 (C1-C2) laminectomy with a resolution of her symptoms. Chiari malformations are sometimes inherited but are often sporadic in nature, and, thus, appropriate diagnosis is key. Our patient is unique in that she presented at an older age, suggesting that atypical etiologies of a chronic cough refractory to conventional treatments must be considered., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Patel et al.)

Carcinoma en cuirasse is a rare cutaneous metastatic presentation of breast cancer with a poor prognosis. We report a female in her 70s with a prior history of left breast ductal carcinoma in situ status post-radiation and lumpectomy who presented with skin thickening of the left breast and a few solid masses in bilateral breasts. Biopsy showed invasive ductal carcinoma of the left breast (estrogen receptor [ER]/progesterone receptor positive [PR], human epidermal growth factor receptor-2 [HER2] negative) and ductal carcinoma in situ of the right breast (ER/PR positive). She underwent a right breast lumpectomy; however, the left breast mastectomy was aborted due to the worsening of her skin findings on preoperative examination. A skin biopsy revealed poorly differentiated invasive ductal carcinoma. She was diagnosed with stage 4 breast cancer, specifically carcinoma en cuirasse. Systemic treatment was initiated, followed by a left breast mastectomy. A surgical biopsy was HER2-positive, and therefore anti-HER2 therapy was given. She remains on maintenance therapy with an excellent response at present.Any unexplained skin findings in breast cancer patients should prompt consideration of carcinoma en cuirasse. With ongoing treatment advances, many newer therapy options are available for metastatic breast cancer. Based on our case, we think that patients with this disease can have better outcomes., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Godbole et al.)